Improving the Appropriateness of Antipsychotic Prescribing for Behavioral and Psychological Symptoms of Dementia (BPSD): A Pilot Study of the Psychotropic Use Monitoring (PUM) Program

In nursing homes, antipsychotic prescribing decisions (APDs) for managing behavioral and psychological symptoms of dementia (BPSD) depend on the nursing staff’s feedback. Inappropriate APDs can result in the lack of timeliness, objectivity and important clinical information when nursing staff’s feedback on residents’ behavior and pharmacotherapy outcomes. Currently, there are no reported interventions for improving psychiatrists’ APDs through nursing staff’s monitoring and feedback processes. This one-group pre-and-post pilot study aimed to evaluate the feasibility and impact of implementing a newly-developed Psychotropic Use Monitoring (PUM) program for improving the appropriateness of APDs in a 50-bed dementia ward of a nursing home. The PUM intervention involved 16 pharmacist-trained nursing staff, who monitored and reported residents’ BPSD changes and psychotropic side effects for 24 weeks, while carrying out their routine care duties. A face-to-face interview was then administered to determine the nursing staff’s perceptions of PUM. Data of 51 residents were collected from hardcopy individual patient records to evaluate the changes in APDs and the number of resident falls before and after implementing PUM. The nursing staff reported increases in their knowledge, awareness, confidence, and actual frequency of monitoring for side effects, as well as their ability in differentiating and managing BPSD (p < 0.05). After PUM, there was a significant increase in the number of APDs due to side effect-related reasons (4 versus 16) (p < 0.031). Although not significant, the number of APDs with no documented reasons (5 versus 9) and the number of resident falls (7 versus 15) appeared to be lesser after PUM. This study demonstrated the nursing staff’s positive participation in PUM intervention, specifically in monitoring and feedback of side effects. Furthermore, a potential exists for PUM to encourage more judicious APDs, which may be useful in settings with heavy patient load, limited human resources and dependence on foreign nursing staff from differing cultural backgrounds.

The Efficacy and Safety of Yokukansankachimpihange for Treating Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: An Open-Label Pilot Study

Previous clinical trials have demonstrated the efficacy of yokukansan, a traditional Japanese medicine, for the treatment of behavioral and psychological symptoms of dementia (BPSD). However, less evidence is available for the treatment of BPSD with yokukansankachimpihange (YKSCH), which consists of yokukansan and two additional herbal ingredients. The present study was conducted to investigate the efficacy and safety of YKSCH for treating BPSD in patients with Alzheimer’s disease (AD). We enrolled outpatients with mild-to-moderate AD who exhibited BPSD and obtained a Neuropsychiatric Inventory (NPI) score of >3 including subscale scores for “agitation”, “anxiety”, “irritability”, and “sleep and night-time behavior change”. A daily YKSCH dose of 7.5 g was administered for 12 weeks with concomitant administration of anti-dementia medication. BPSD was evaluated using the NPI at baseline and every 4 weeks during the intervention. We also examined apathy using the Japanese translation of the Apathy Scale, the short version of the Japanese version of the Zarit Caregiver Burden Interview, and the Modified Crichton Rating Scale for Predicting Activities of Daily Living. Cognitive dysfunction was evaluated using the Mini Mental State Examination and the AD Assessment Scale-Cognitive (Japanese version). Five participants were enrolled. The NPI total score tended to decrease between the baseline and 8-week evaluations during the YKSCH intervention (Wilcoxon signed rank test, P = 0.063). In terms of the NPI subscale scores, “apathy”, “agitation”, “delusions”, and “sleep and night-time behavior change” decreased after the intervention in those who exhibited each symptom at baseline. There were no significant differences in the other scores examined. No serious adverse events were observed. YKSCH could ameliorate BPSD in patients with mild-to-moderate AD with agitation, anxiety, irritability, and sleep and night-time behavior change, and it was well-tolerated.

Role of antipsychotics for treating behavioral and psychological symptoms of dementia

Over the past three decades, concerns about the high prevalence of antipsychotic use in the nursing homes （NHs） for the management of behavioral and psychological symptoms of dementia continue to be emphasized and intervened by many. However, despite the numerous side effects and the recent blackbox warning by the United States Food and Drug Administration about the increased risks for stroke and sudden death associated with the use of antipsychotics in dementia, the preva-lence of antipsychotic use in NHs remains high. While the use of antipsychotics appeared to have modest effcacy in reducing symptoms of aggression and psychosis in dementia, there is insuffcient evidence to routinely rec-ommend the use of alternative psychopharmacological treatments for these symptoms. Hence, clinicians have to balance the safety warnings against the need to treat these symptoms in order to prevent harm to the resident that may result from his/her dangerous behaviors. Although the use of antipsychotics may be warranted in some cases, organizational, resource and training support should be provided to encourage and equip NH staff to participate in interventions so as to minimize inappropriate use of these medicines in NHs. This review will discuss the place in therapy, the trend and appropriateness of antipsychotic use in NHs, as well as the effectiveness of current and future strategies for reducing antipsychotic use in the NHs.

Gabapentin for the treatment of behavioral and psychological symptoms of dementia

Objective: To examine the efficacy of gabapentin for the treatment of behavioral and psychological symptoms of dementia (BPSD). Design: A retrospective chart review. Settings: Tertiary care geriatric psychiatry inpatient unit. Participants: 230 patients with BPSD. Measurements: The socio-demographic information, type of behaviors, co-morbid psychiatric and medical diagnoses, daily doses of medications and side-effects were recorded. Results: Of the 230 patients, 22 were treated with gabapentin. Twenty of these patients were on a combination of gabapentin and an antipsychotic medication while two patients were treated with gabapentin monotherapy. Eighteen of the 20 patients in the combination group tolerated the treatments with little or no side effects as did the two patients in the monotherapy group. Conclusions: Gabapentin may be a safe option for the treatment of BPSD in combination with antipsychotic medications. Gabapentin may also be effective as monotherapy in certain patients with BPSD.

Quantitative evaluation of severity of behavioral and psychological symptoms of dementia in patients with vascular dementia

To quantitatively evaluate severity of behavioral and psychological symptoms of dementia(BPSD)for vascular dementia(VD).Changes of 51 patients with VD in BPSD between the first and 24th week were assessed using the Neuropsychiatric Inventory(NPI)and the behavioral pathology in Alzheimer’s disease(BEHAVE-AD)rating scale,in detrended fluctuation analysis(DFA)represented by diurnal activity(DA),evening activity(EA),and nocturnal activity(NA),and the relationships were analyzed.The subscores of activity disturbances,diurnal rhythm disturbances,and anxieties and phobias in the BEHAVE-AD score,and that of agitation,irritability,and sleep disorder in the NPI score were significantly increased compared with the first week,as was for the changes for EA in the DFA value.A linear correlation was observed between the changes of activity disturbances plus anxieties and phobias,and those of DA,and between the development of diurnal rhythm and those of EA,the vehement and autism scores and those of DA,and the difference in sleep disorder scores and those of EA,respectively.Analysis of DA,NA,and EA may reflect the fluctuational degrees of VD-BPSD,can provide a useful assessment of VD-BPSD accompanied by clinical scores for VD.

An association between the location of white matter changes and the behavioral and psychological symptoms of dementia in Alzheimer's disease patients

Objective:The frontal lobe may be involved in circuits associated with depression,apathy,aggression,and other psychiatric symptoms.Although white matter changes(WMC)are related to the severity of behavioral and psychological symptoms of dementia(BPSD)in patients with Alzheimer’s disease(AD),it is unclear which part of the WMC may play the most important role in BPSD.This study was designed to investigate the relationship between the location of WMC and the severity of BPSD in AD patients.Methods:Among patients diagnosed with Alzheimer’s disease between 2009 and2014,387 patients were retrospectively reviewed after those with pre‐existing organic brain syndrome,psychiatric diseases,or toxic‐metabolic encephalopathy were excluded.Patients’demographic and laboratory data,WMC measured with brain computed tomography and scored using the age‐related white matter changes(ARWMC)scale,and neuropsychological tests,including the cognitive abilities screening instrument(CASI),the Mini‐Mental State Examination(MMSE),the clinical dementia rating scale with sum‐box(CDR‐SB),and the neuropsychiatric inventory(NPI)were analyzed.Results:There was no significant difference in the NPI between patients with and without a history of stroke,hypertension,and diabetes.No significant difference in the NPI was identified between different sexes or different Apolipoprotein E(APOE)alleles.The NPI score was significantly correlated with the duration of education(r=–0.4515,P=0.0172),CASI(r=–0.2915,P<0.0001),MMSE(r=–0.8476,P<0.0001),and CDR‐SB(r=2.2839,P<0.0001).WMC in the right frontal lobe showed a significant difference in NPI in comparison to those without WMC(P=0.0255).After adjusting for age,duration of education,and CASI,WMC in the right frontal lobe remained significantly associated with the NPI score(β=3.8934,P=0.042).Conclusions:WMC involving the right frontal lobe may play an important role in the BPSD in AD patients during their dementia diagnosis.Further studies are necessary to confirm whether controlling the risk factors of WMC can slow the progression of BPSD.

老年期痴呆的BPSD非药物治疗及其与ApoE基因多态性相关性的临床研究

目的分析老年期痴呆的行为精神症状(behavioral and psychological symptom of dementia,BPSD)的非药物治疗效果及其与载脂蛋白E(apolipoprotein E,ApoE)基因多态性的关系。方法选取2016年1月至2022年12月江西省人民医院收治的90例老年期痴呆患者为研究对象,根据随机数字表法将其分为常规组、对照组和观察组,每组各30例。常规组患者给予盐酸美金刚片治疗,对照组患者在常规组基础上加以音乐疗法,观察组患者在常规组基础上加以重复经颅磁刺激治疗,三组均连续治疗12周。比较三组患者的BPSD严重程度、痴呆严重程度、认知功能、日常生活能力、ApoE基因多态性。结果治疗前,三组患者的神经精神问卷(neuropsychiatric inventory,NPI)、临床痴呆评定量表(clinical dementia rating,CDR)、简明精神状态检查量表(mini-mental state examination,MMSE)、日常生活能力评定量表(activity of daily living scale,ADL)评分比较差异均无统计学意义(P>0.05);治疗后,三组患者的NPI、CDR评分均显著低于本组治疗前,MMSE、ADL评分均显著高于本组治疗前(P<0.05);观察组和对照组患者的NPI、CDR评分均显著低于常规组,MMSE、ADL评分均显著高于常规组(P<0.05)。ApoE共有ε2、ε3、ε4三种等位基因,其中ε3表达频率最高,共55例,其次为ε4和ε2;三组患者的ApoE不同基因检出率比较差异无统计学意义(P>0.05)。ApoEε4型患者的NPI评分显著高于ApoEε3型与ApoEε2型(P<0.05)。结论非药物治疗老年期痴呆患者效果显著,可减轻BPSD和痴呆表现,提高患者的认知功能和日常生活能力,ApoEε4型基因与老年期痴呆患者的BPSD存在紧密联系。

Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia

Behavioral and psychological symptoms including agitation are common in dementia,and are associated with decreased quality of life,increased risk of institutionalization,and greater patient and caregiver distress.Pharmacological agents used for management of behavioral and psychological symptoms of dementia are limited by their tolerability,prompting a need for identifying efficacious and safe pharmacological treatments for managing agitation in dementia.The combination of dextromethorphan and quinidine sulfate is approved for pseudobulbar affect,and may be effective in managing agitation in dementia.A review of literature found only one randomized controlled trial that evaluated the use of dextromethorphan-quinidine for the management of agitation in dementia when compared to placebo.Data from this trial demonstrated that dextromethorphan-quinidine decreased agitation in dementia,and was well tolerated.Although promising,further research is needed before dextromethorphan-quinidine combination can be accepted as a standard treatment for agitation in dementia.

失智老年人精神行为症状理论研究进展

综述理论的本质、理论在老年失智领域的发展历程及不同理论类型,通过全面探讨这些理论在老年失智病人治疗和照护中的重要性及其在实践中的应用效果,以期为失智病人提供更加有效的支持与干预策略。

痴呆特别照料单元的现状和展望

在痴呆负担日益沉重的背景下,痴呆特别照料单元(Dementia Special Care Units,DSCU)作为旨在为阿尔茨海默病等痴呆症患者提供专病照料的有效手段逐渐受到重视。经过长期发展,DSCU在物理空间、人力资源建设、效果评价等方面已经形成成熟的建设策略,实践证明规范的DSCU可以帮助控制痴呆相关精神行为异常(Behavioral and psychological symptoms of dementia,BPSD),使痴呆患者获益。本文就DSCU的发展、建设、展望作一综述。

甘露特钠联合抗癫痫药物治疗阿尔茨海默病伴发癫痫及痴呆行为精神症状患者一例

目的 探究阿尔茨海默病(AD)伴发癫痫及痴呆行为精神症状(BPSD)患者的用药选择。方法 报道1例患者男性71岁,根据临床、影像学及既往史诊断为AD合并癫痫及BPSD,应用甘露特钠、左乙拉西坦联合治疗。结果 本例患者应用甘露特钠联合抗癫痫药物治疗后,在抗癫痫、改善认知功能、精神行为异常方面取得良好疗效。结论 甘露特钠联合抗癫药药物治疗AD合并癫痫及BPSD患者有较好的疗效及较高的安全性。

探讨多奈哌齐联合奥氮平治疗老年痴呆伴发精神行为症状患者的临床价值

目的 探讨采用多奈哌齐联合奥氮平药物对老年痴呆伴发精神行为症状患者展开疾病治疗的价值。方法 非随机选取枣庄市精神卫生中心于2020年3月—2023年5月收治的68例老年痴呆合并精神行为症状患者为研究对象。依据治疗方法不同分组,参照组(34例)给予奥氮平药物治疗,研究组(34例)给予多奈哌齐+奥氮平药物治疗。比较两组患者的用药总有效率、不良反应情况、日常生活活动评分以及简易智力状态检查评分。结果 研究组治疗总有效率为94.12%(32/34),高于参照组的76.47%(26/34),差异有统计学意义(χ^(2)=4.220,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组日常生活活动评分以及简易智力状态检查评分比较,差异无统计学意义(P均>0.05)。治疗后,两组均较治疗前改善,且研究组改善更为明显,差异有统计学意义(P均<0.05)。结论 采用多奈哌齐联合奥氮平治疗老年痴呆伴发精神行为症状患者的疗效较好,无额外不良反应,可以有效增强患者日常生活活动能力和改善认知功能,有利于改善患者预后。

多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性对照研究

目的:探讨多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性。方法:103例伴精神行为症状的痴呆病人随机分为多奈哌齐合并奥氮平组与单用奥氮平组。治疗前和研究结束时进行简易智力状态检查(MMSE)评分,在治疗2、4、6、8周末以痴呆病理行为评定量表(BE-HAVE-AD)减分率评定疗效:≥60%为显效,≥30%为有效,<30%为无效。以副反应量表(TESS)评定记录治疗中各项药物不良反应。结果:多奈哌齐合并奥氮平组MMSE评分较治疗前提高2分以上,治疗结束后组内比较差异有统计学意义(t=2.060,P<0.05)。治疗前后BE-HAVE-AD量表评分两组组内比较,至第4周末时均明显下降,差异有显著统计学意义(P<0.01或P<0.05)。多奈哌齐合并奥氮平组有效率为88.46%,显效率为67.31%;单用奥氮平组有效率70.59%,显效率为45.10%,两组比较有效率和显效率差异均有统计学意义(χ2=5.067,P<0.05;χ2=5.701,P<0.05)。两组均无不能耐受的不良药物反应。结论:多奈哌齐合并奥氮平治疗老年痴呆精神行为症状安全有效且优于单用奥氮平。

奥氮平或喹硫平联合多奈哌齐治疗老年痴呆精神行为症状的疗效和安全性研究

目的探讨奥氮平或喹硫平联合多奈哌齐治疗老年痴呆精神行为症状的疗效和安全性。方法将103例伴精神行为症状的痴呆患者随机分为奥氮平联合多奈哌齐组(A组)与喹硫平联合多奈哌齐组(B组)。治疗前和研究结束时进行简易智力状态检查(MMSE)评分。在治疗后的第2、4、6、8周末以痴呆病理行为评定量表(BEHAVE-AD)减分率评定疗效,以副反应量表(TESS)记录治疗中各项药物不良反应。结果两组MMSE评分均较治疗前提高2分以上,治疗结束后两组组内比较,差异均有统计学意义(均P<0.05)。治疗前后BEHAVE-AD量表评分两组组内比较,至第4周末时均明显下降,差异有高度统计学意义(均P<0.01)。A组有效率为88.46%(46/52),显著有效率为67.31%(35/52);B组有效率为86.27%(44/51),显著有效率为64.71%(33/51),两组疗效比较差异无统计学意义(P>0.05)。两组均无不能耐受的不良药物反应。结论奥氮平或喹硫平联合多奈哌齐治疗老年痴呆精神行为症状安全有效。

阿尔茨海默病和血管性痴呆患者的认知功能和精神行为症状

目的:比较轻中度阿尔茨海默病(Alzheimer's disease,AD)和血管性痴呆(vascular de-mentia,VD)患者的认知功能损害和精神行为症状的特点。方法:本研究为病例对照研究。选取神经内科老年记忆障碍门诊中就诊的轻中度老年期痴呆患者共115例,均符合美国精神病学会精神障碍诊断和统计手册第四版(Diagnostic and Statistical Manual of Mental disorders,Fourth Edition,DSM-Ⅳ)的痴呆诊断标准。AD组61例,符合NINCDS-ADRDA可能或很可能AD诊断标准;VD组54例,符合NINDS-AIREN可能或很可能VD诊断标准中的皮质下缺血性血管性痴呆。采用简易精神状态评定表(Mini-Mental StateExamination,MMSE),世界卫生组织-加利福尼亚洛杉矶大学听觉词语学习测验(World Health Organiza-tion-University of California,Los Angeles,auditory verbal learning test,WHO-UCLA AVLT),画钟测验(Clock Drawing Test,CDT),神经精神问卷(Neuropsychiatric Inventory,NPI)对两组患者从记忆力、语言、注意力等方面以及妄想、幻觉、激越、抑郁、淡漠、易激惹、异常的运动行为等方面进行评估。结果:AD患者较VD患者MMSE量表中的语言能力,WHO-UCLA AVLT测评中的延迟回忆和长时延迟再认减退明显(均P<0.05),VD患者较AD患者MMSE中的注意力减退明显(P<0.05);NPI量表中,AD患者淡漠、激越、易激惹、异常运动行为明显多于VD患者(P<0.05),抑郁少于VD患者(P<0.05)。结论:AD和VD患者在认知功能损害和精神行为症状方面存在差异,AD患者的语言能力、记忆力较差,而VD患者的注意力较差;AD淡漠、激越、易激惹、异常运动行为多见,VD抑郁多见。临床工作中对痴呆患者的认知功能和精神行为症状测评有助于AD和VD的鉴别。

美金刚联合脑电磁治疗阿尔茨海默病痴呆的行为精神症状的疗效观察

目的探讨美金刚联合脑电磁治疗阿尔茨海默病(AD)痴呆的行为精神症状(BPSD)的研究。方法选取2017年1月—2020年1月在浙江省人民医院就诊的AD伴BPSD患者122例,按照随机表法分为观察组和对照组,各61例。对照组口服美金刚片;观察组在对照组基础上结合脑电磁治疗。两组疗程均为12周。比较两组疗效,以及治疗前后简易精神状态检查(MMSE)、日常生活活动(ADL)、AD病理行为症状量表(BEHAVE-AD)、神经精神量表(NPI)评分及脑源性神经营养因子(BDNF)、多巴胺(DA)、5-羟色胺(5-HT)水平变化。结果观察组治疗后总有效率高于对照组(P<0.05)。观察组治疗前后MMSE评分、ADL评分、BEHAVE-AD评分、NPI总分和NPI苦恼因子评分的差值高于对照组(P<0.05)。观察组治疗前后血清BDNF、DA和5-HT水平的差值高于对照组(P<0.05)。结论美金刚联合脑电磁治疗AD患者BPSD临床疗效较好,值得临床借鉴。

美金刚联合小剂量奥氮平治疗阿尔兹海默病伴有行为和精神症状患者临床研究

目的观察美金刚联合小剂量奥氮平治疗伴有行为和精神症状的阿尔兹海默病(AD)患者的疗效及对患者认知功能的影响。方法将87例AD伴行为和精神症状患者随机分为美金刚单药治疗组(单药治疗组)和联合奥氮平治疗组(联合治疗组),对所有入组患者在治疗前及治疗4、12周末均行AD病理行为(Behave-AD)评分、简易智力状态检查(MMSE)评定,并对评定结果进行比较。结果 2组患者治疗前Behave-AD和MMSE评分比较差异均无统计学意义(t=0.47、0.33,P>0.05)。治疗第4周末2组患者Behave-AD评分均较治疗前显著下降(t=7.02、9.79,P<0.05),且联合治疗组较单药治疗组下降更显著(t=2.35,P<0.05);2组患者MMSE评分均较治疗前显著升高(t=8.15、5.82,P<0.05),但2组患者之间MMSE评分比较差异无统计学意义(t=0.16,P>0.05)。治疗第12周末2组患者Behave-AD评分均较治疗前显著下降(t=10.94、12.64,P<0.05);2组患者MMSE评分均较治疗前显著升高(t=14.21、14.82,P<0.05),但2组患者之间MMSE评分比较差异无统计学意义(t=0.24,P>0.05)。治疗第12周末2组患者Behave-AD评分均较治疗第4周末显著下降(t=3.93,3.99,P<0.05),且联合治疗组较单药治疗组下降更显著(t=2.12,P<0.05);2组患者MMSE评分均较治疗第4周末显著升高(t=5.49、5.05,P<0.05),但2组患者之间MMSE评分比较差异无统计学意义(t=14.82,P<0.05)。结论美金刚联合小剂量奥氮平治疗AD伴行为和精神症状患者较美金刚单药治疗更能减轻其精神行为症状,但对认知功能改善二者效果相当。

164例住院老年期痴呆患者的精神和行为障碍

目的 研究老年期痴呆病人的精神和行为障碍(BPSD)。方法 采用BEHAVE-AD量表对164例住院的老年期痴呆病人进行评定。结果 所有病例均有不同程度的BPSD,其中以行为紊乱、攻击行为、日夜节律紊乱和偏执与妄想多见,且阿尔茨海默病(AD)和血管性痴呆(VD)大致相似。结论 DPSD的发生率极高,对老年期痴呆的诊断、治疗、预后等有重要影响,应予重视和加强研究。

醒脑静联合尼莫地平治疗血管性痴呆及对患者精神行为症状的影响

目的探讨醒脑静联合尼莫地平治疗血管性痴呆的疗效及其对患者精神行为症状的影响。方法将收治的血管性痴呆患者86例,按照简单数字表法随机分为对照组和观察组各43例。对照组给予尼莫地平治疗,观察组给予醒脑静注射液联合尼莫地平治疗。比较两组患者的临床治疗效果,并对患者精神行为症状的影响进行评价。结果观察组总有效率90.70%高于对照组的62.79%,差异具有统计学意义(P<0.05)。观察组患者简明智能状态检查量表(MMSE)评分(18.62±4.83)分和日常生活活动能力量表(ADL)评分(34.12±7.82)分均高于对照组患者的(15.75±4.60)分和(28.35±7.46)分,差异具有统计学意义(P<0.01)。观察组患者长谷川痴呆量表(HDS)评分(23.65±4.21)分高于对照组的(21.32±4.15)分,差异具有统计学意义(P<0.01)。观察组患者痴呆病理行为评定量表(BEHAVEAD)评分(11.84±4.08)分低于对照组患者的(13.92±4.23)分,差异具有统计学意义(P<0.01)。结论醒脑静注射液联合尼莫地平治疗血管性痴呆疗效显著,可有效改善患者认知功能和精神状态,提高患者生活质量,具有较好的临床应用价值。

老年期痴呆伴发精神行为障碍的家庭医疗干预模式

目的·探讨老年期痴呆伴发精神行为障碍的家庭医疗干预模式。方法·从上海市长宁区街道中整群抽取4个街道,按照入组标准选取研究对象,分为干预组(71例)和对照组(70例)。针对干预组提供精神科医师上门服务,给予药物治疗和心理社会干预。分别在基线时、6个月末、12个月末进行老年期痴呆患者病理行为量表(BEHAVE-AD)、简易精神状态评定量表(MMSE)、日常生活能力量表(ADL)、老年期痴呆生活质量量表(QOL-AD)、生活质量综合评定问卷(GQOLI-74)评分。结果·(1)对干预前2组患者的BEHAVE-AD总分及各因子分进行比较,差异无统计学意义(P>0.05);重复测量方差分析显示,评定时间主效应显著(P<0.001),BEHAVE-AD总分、情感障碍和焦虑恐惧因子分组别主效应均存在显著差异(P<0.001),BEHAVE-AD总分、妄想和情感障碍因子分组别与时间交互作用均存在显著差异(P<0.05)。(2)BEHAVE-AD评分组间比较:在6个月末时,就幻觉、昼夜节律紊乱、情感障碍和焦虑恐惧因子分而言,干预组均明显优于对照组,差异有统计学意义(P<0.01);在12个月末时,就BEHAVE-AD总分及妄想、行为紊乱、情感障碍和焦虑恐惧因子分而言,干预组均优于对照组,差异有统计学意义(P<0.01)。(3)对干预前2组患者的MMSE、ADL、QOL-AD、GQOLI-74评分进行比较,差异无统计学意义(P>0.05);重复测量方差分析显示,评定时间主效应显著(P<0.001),MMSE和QOL-AD评分组别主效应均存在显著差异(P<0.001),MMSE、ADL、QOL-AD、GQOLI-74评分组别与时间交互作用均存在显著差异(P<0.05)。(4)MMSE、ADL、QOLAD、GQOLI-74评分组间比较:在6个月末时,干预组MMSE评分优于对照组,差异有统计学意义(P<0.05);在12个月末时,就MMSE、ADL、QOL-AD、GQOLI-74评分而言,干预组均优于对照组,差异有统计学意义(P<0.05)。结论·精神科医师上门服务并整合多学科团队成员的家庭医疗模式对改善老年期痴呆患者精神行为症状有效,可以提高患者和照料者的生活质量,持续开展效果更明显。